Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Pulmicort Turbuhaler · 1 trial · 1 indication
Change in morning peak expiratory flow (mPEF) from baseline (mean of the last 14 days of the period on Pulmicort Turbuhaler) to Week 6 (mean of the last 14 days of the period on Pulmicort Respules)
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Four weeks treatment with either Pulmicort Turbuhaler at a dose of 400 μg or 200 ug twice daily, followed by 6 weeks treatment with Pulmicort Respules at a dose of 1.0 mg twice daily or 0.5 mg twice daily/1.0 mg once daily |
| 2 | EXPERIMENTAL | Pulmicort Turbuhaler at a dose of 200 μg twice daily and Pulmicort Respules at a dose of 0.5 mg twice daily or 1.0 mg once daily (low dose) |
| Name | Type | Description |
|---|---|---|
| Budesonide | DRUG | Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks |
| Pulmicort Turbuhaler | DRUG | Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler |
Inclusion Criteria: * Provision of informed consent prior to any study specific procedures. * A minimum of 6 months documented history of asthma according to the JGL 2006 definition * Asthma patients under prescribed treatment with ICS at least 3 months before Visit 2. Exclusion Criteria: * Curre...
Pulmicort Turbuhaler is used for the treatment of asthma. It is an inhaled corticosteroid that helps reduce inflammation in the airways, improving asthma control. The drug is being developed by AstraZeneca PLC (ticker: AZN) and is currently in Phase 3 clinical development for this indication.
Pulmicort Turbuhaler contains budesonide, a corticosteroid that works by reducing inflammation in the airways. It is a small molecule that acts locally in the lungs to decrease swelling and mucus production, helping to prevent asthma symptoms and improve lung function.
Pulmicort Turbuhaler is developed by AstraZeneca PLC, a multinational pharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical trials to evaluate the efficacy and safety of this drug for the treatment of asthma.
Pulmicort Turbuhaler is in Phase 3 clinical development for asthma. It is an investigational drug and has not yet been approved by regulatory authorities. One Phase 3 trial has been completed, and the drug is not currently in active clinical trials.
Pulmicort Turbuhaler has been studied in one completed Phase 3 clinical trial, identified as NCT00855959. This trial, titled 'Study to Evaluate Efficacy and Safety of Pulmicort Respules in Japanese Adult Asthmatic Patients,' enrolled 108 participants aged 16 years and older in Japan.
Pulmicort Turbuhaler and Pulmicort Respules are both formulations of budesonide, but they are different delivery devices. The Turbuhaler is a dry powder inhaler, while Respules are nebulized suspension. The clinical trial NCT00855959 evaluated Pulmicort Respules in Japanese adult asthmatic patients.